Inclusion: YES n 121 130 146 Exacerbation rate/year 1.64 1.13 0.94 Comparison versus placebo Rate ratio 0.69 0.57 (mepolizumab/placebo) 95% CI 0.49, 0.98 0.41, 0.80 demonstrated at screening ≥ Inclusion: No n 21 30 35 Exacerbation rate/year 1.31 1.23 1.20 Comparison versus placebo Rate ratio 0.94 0.91 (mepolizumab/placebo) 95% CI 0.43, 2.07 0.44, 1.90 Inclusion: Yes n 167 155 155 Exacerbation rate/year 1.75 0.81 0.67 Comparison versus placebo Rate ratio 0.46 0.38 (mepolizumab/placebo) 95% CI 0.33, 0.64 0.27, 0.53 in previous 12 months OR at screening2 ≥ ≥ documented in the previous 12 months ≥ n 23 34 39 Exacerbation rate/year 1.52 1.62 1.25 Comparison versus placebo
Inclusion: YES n 121 130 146 Exacerbation rate/year 1.64 1.13 0.94 Comparison versus placebo Rate ratio (mepolizumab/placebo) 0.69 0.57 95% CI 0.49, 0.98 0.41, 0.80 ≥ demonstrated at screening Inclusion: No n 21 30 35 Exacerbation rate/year 1.31 1.23 1.20 Comparison versus placebo Rate ratio (mepolizumab/placebo) 0.94 0.91 95% CI 0.43, 2.07 0.44, 1.90 Inclusion: Yes n 167 155 155 Exacerbation rate/year 1.75 0.81 0.67 Comparison versus placebo Rate ratio (mepolizumab/placebo) 0.46 0.38 95% CI 0.33, 0.64 0.27, 0.53 ≥ in previous 12 months OR ≥ at screening2 ≥ documented in the previous 12 months n 23 34 39 Exacerbation rate/year 1.52 1.62 1.25 Comparison versus placebo
auspar-mepolizumab-rch-170308-cer.docx